Last edition
News about "Galleri Multi-Cancer Early Detection"
Grail Submits Final PMA Module to FDA for Galleri Multi-Cancer Early Detection Test
Grail files the final Premarket Approval module with the FDA for its Breakthrough Device-designated Galleri test, supported by data from over 25,000 participants in PATHFINDER 2 and the NHS-Galleri trial.
Galleri Multi-Cancer Early Detection | 30/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members